Therapex steps up to the challenge to develop innovative therapeutics by leveraging excellent scientific experience

Therapex is dedicated to creating new standards of care for cancer patients with the potential to be the best or first in class

Therapex builds a diversified pipeline with assets that inhibit key oncogenic drivers or boost the immune system

Therapex promises to reach the apex of therapeutics based on our expertise of developing novel medicines.
The Apex of
Therapeutics
PIPELINE
Immuno-Oncology
Developing small molecule-based anti-cancer drugs for treating the solid tumors resistant to the existing therapeutic agents
Targeted Oncology
Developing precision medicines that targets mutated-EGFR in non-small cell lung cancer (NSCLC) patients
PROTAC
Developing the targeted protein degraders that converts the undruggable to the druggable
R&D
Creative thinking and innovative technology
Therapex endeavors to provide better solutions for the patients with incurable diseases
view more
Merit
Competitive new drug
development technology
Experts in
Drug Discovery
Specialty in drug R&D and broad web
over human network
In-silico
Modeling
Agility in lead generations with expertise on
molecular modeling and design
In-house
Infra
Proficiency in medical chemistry and pharmacological
assessment that expedite the research progress
Therapeutic
New Modality
Know-how on developing PROTACs that directly degrade
and eradicate the disease-related bio-molecules
Media release
view more
NEWS
2024.04.12

Therapex Suggests Best-in-Class Potential for 'TRX-211-399' at AACR An..

│Shows improved selectivity and blood-brain barrier permeability comp..
NEWS
2024.03.26

Therapex Launches Attack on Tagrisso-Resistant Lung Cancer with Target..

Approval of an Investigational New Drug application (IND) for the Pha..
NEWS
2023.11.21

Therapex Unveils “Broad Spectrum” Strategy for Fourth-Generation Lung ..

Therapex has entered clinical trials to develop a fourth-generation d..
NEWS
2023.10.24

Therapex Presents Poster on Anticancer Agent for Non-Small Cell Lung C..

Therapex CEO Koo Lee PhD (left) presenting the follow-up results of t..
NEWS
2023.10.10

Therapex Presents Preclinical Study Results of Non-Small Cell Lung Can..

Therapex, a subsidiary of Gradient, announced on October 10th that it..
NEWS
2023.08.29

FDA Approves Therapex's Targeted Anti-Cancer Agent for Non-Small Cell ..

TRX-221's anti-tumor effect in EGFR C797S mutant non-small cell lung ..
NEWS
2023.07.26

Therapex's Innovative “Broad-Spectrum” Approach in EGFR-Targeted Antic..

Experienced anticancer drug development team leads clinical trials fo..
NEWS
2023.07.25

EGFR Lung Cancer Game Changer “Tagrisso”, In Development to Expand Ind..

EGFR Lung Cancer Game Changer "Tagrisso," In Development to..
NEWS
2023.07.16

The Rapidly Emerging Platform, PROTAC, Known as the ‘Kiss of Death’ ..

Bioplus Interphex Korea (BIX) 2023 opened at COEX, Seoul from July 12..
NEWS
2023.04.19

"TRX-221" from Therapex Grabs the Attention of Global Cancer..

Preclinical results announced for the fourth-generation lung cancer d..